Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), a protein that plays a key role in the survival and spread of certain types of B-cell cancers. By forming a covalent bond with the BTK active site, ibrutinib blocks its activity. This disrupts important signaling pathways that cancerous B-cells use to grow, move, and stick to other cells.

By inhibiting BTK, ibrutinib can slow down or stop the growth of malignant B-cells, making it effective in treating certain blood cancers. In clinical studies, ibrutinib has shown the ability to reduce cancer cell proliferation and survival, as well as interfere with their movement and ability to attach to other tissues. This mechanism is especially important in diseases where B-cells are the source of the cancer, such as some lymphomas and leukemias.

ibrutinib

Common brand names

Approved use in